AI assistant
Eledon Pharmaceuticals, Inc. — Director's Dealing 2017
May 12, 2017
33900_dirs_2017-05-11_cf384430-d2c7-467b-b3fa-f4ef0c6fdf7a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Novus Therapeutics, Inc. (NVUS)
CIK: 0001404281
Period of Report: 2017-05-10
Reporting Person: TURKEL CATHERINE C. (Chief Development Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 13408 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $19.76 | 2025-12-29 | Common Stock (4290) | Direct | |
| Stock Option (Right to Buy) | $19.76 | 2025-12-29 | Common Stock (536) | Direct | |
| Stock Option (Right to Buy) | $19.76 | 2026-12-15 | Common Stock (1073) | Direct |
Footnotes
F1: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.
F2: This option represents a right to purchase a total of 4,290 shares of the Issuer's Common Stock one quarter of which became fully vested and exercisable on December 30, 2016, with the remaining 3,217.5 shares vesting in equal quarterly installments over the following three years.
F3: This option represents a right to purchase a total of 536 shares of the Issuer's Common Stock which have vested in full as a result of the attainment of performance milestones.
F4: This option represents a right to purchase a total of 1,073 shares of the Issuer's Common Stock one quarter of which became fully vested and exercisable on May 9, 2017, with the remaining 804.75 shares vesting in equal quarterly installments over the following three years.